Starpharma Holdings Limited · ASX:SPL
Starpharma — Australian Biotechnology Expo 2005
18 slides from Starpharma's conference presentation, Aug 9, 2005
Slide 1: CEO Presentation Australian Biotechnology Expo
9 August 2005 CEO PRESENTATION AUSTRALIAN BIOTECHNOLOGY EXPO Attached is a copy of Dr John W Raff’s presentation to the 2005 Emerging Growth Capital Annual Australian Biotechnology Expo, held in conjunction with the Australian Stock Exchange in Sydney today. _________________________________________
Slide 2: Starpharma Holdings Limited (ASX: SPL)
Australian Biotech Expo 9 August 2005 Starpharma Holdings Limited (ASX: SPL) Dr John W. Raff CEO Starpharma 1
Slide 3: Who is Starpharma?
Who is Starpharma? Business: Globally pre-eminent in the Development and commercialisation of new pharmaceuticals using ‘dendrimers’ (highly defined nano-scale structures) Competitive First and only pharmaceutical development company to have had the Advantage: US Food & Drug Administration (“FDA”) a
Slide 4: Nanotechnology
Nanotechnology • Purposeful manipulation of matter smaller than 100 nanometres (“nm”). • Nanotechnology will revolutionise manufacturing and pharmaceutical compounds. • Nanotechnology is the largest US Federally funded science initiative since it decided to put a man on the moon. (In 2004, US Govern
Slide 5: Nanopharmaceuticals
Nanopharmaceuticals We are in the right place at the right time biotechnology nanotechnology • c. 50% of all new drugs derived • “Revenue from nanotechnology-enabled products to equal IT and Telecom by from biotechnology companies. 2014, exceed biotech by 10 times.” • Big Pharma pipeline thin: many
Slide 6: Well-defined structures are everything: Dendrimers
Nanopharmaceuticals Well- defined structures are everything: Dendrimers • Regulatory Authorities around the world emphasise that nanostructures must be well defined for medicinal use. • Starpharma is a world leader in defined synthetic nanostructures : Dendrimers – IP ownership e n dr i m e r : a we
Slide 7: Starpharma's Growth Strategy and Drivers of Value
Starpharma’s Growth Strategy and Drivers of Value Product Focus and Leverage of Shareholders’ Funds • VivaGel™ – Further clinical development; advancement to efficacy trials – Line extensions: Expanded indications (other STIs) and applications (condom coating) • New Dendrimer Products through in-hou
Slide 8: VivaGel: Topical Vaginal Gel for the prevention of HIV and STIs
VivaGelTM Topical Vaginal Gel for the prevention of HIV and STIs What does it Safe sex offer? • a way for a women to avoid STIs • discrete with broad cultural acceptability • female controlled (unlike condom). How does it Broad spectrum microbicide work? •To prevent the transmission of HIV, genital
Slide 9: VivaGel: World's first defined nanopharmaceutical tested in humans
VivaGelTM World’s first defined nanopharmaceutical tested in humans. Development Stage: Line Extensions: 2004: Completed initial •Combination products Phase I (IND). (NIH Funding) 2005: Expanded clinical •Condom coatings program VivaGelTMTM VivaGel packaged packaged into pre- into pre- filled filled
Slide 10: VivaGel Product Benefits
VivaGel™ Product Benefits A practical and versatile microbicide Percentage of macaques protected 100 Evidence to date suggests 5% w/w VivaGel™ from SHIV infection that VivaGel™ is: 75 Base Gel Control 50 • Potent activity against HIV/SHIV 25 demonstrated in vitro and in vivo 0 • Active against other
Slide 11: VivaGel Commercial Strategy
VivaGel™ Commercial Strategy •Initial focus on market in developed world. •Pursue HIV & Genital Herpes indications first •Subsequently: continue evaluation of product for additional indications (other STIs, e.g. Chlamydia, HPV etc) •Parallel development of combination microbicides •Line extension vi
Slide 12: Starpharma's Development Portfolio
Starpharma’s Development Portfolio Products and Partnered Projects Microbicides • VivaGel™ Microbicides • Pipeline of expanded •Combination microbicide (NIH) indications •Condom coatings Glycodendrimers Anti-Virals (IRL) •Influenza •RSV Diabetes Wound Healing, (ChemGenex) Inflammation and Angiogenes
Slide 13: Dendritic Nanotechnologies Inc. (DNT)
Dendritic Nanotechnologies Inc. (DNT) Significant Value Driver and Strategic Partner • Private US company www.dnanotech.com • Existing revenue streams from deals with: – Dow Chemical Company, – Pfizer, Inc., – Sigma Aldrich, – US Dept. Defense • Dow recently transferred their entire dendrimer nanote
Slide 14: Recent US perspectives on Starpharma
Recent US perspectives on Starpharma “Top “Top55Nanotech NanotechBreakthroughs Breakthroughs “Top for 2004” “TopNanotech NanotechBuys Buysfor for2005” 2005” for 2004” “We “Weexpect expectgreat greatthings thingstoto Forbes Forbes/ / Nanotech come Nanotech comefromfrom[Starpharma] [Starpharma]andand
Slide 15: US demand for Starpharma shares: Net Depositary Receipt Adoption
US demand for Starpharma shares 600000 Net Depositary Receipt Adoption 500000 (1ADR = 10 SPL shares) …the …thetaketakeupupofofStarpharma’s Starpharma’sADRADR program since January 2005 launch program since January 2005 launch 400000 date dateisissaid saidtotobe be“exceptional” “exceptional” Source:
Slide 16: Financials and Shareholder Profile
Financials and Shareholder Profile •$8.2 million cash in the Bank (June 30) •Existing leverage of development spend through NIH grant US$5.4M and AU$5.6M of P3 funding •Several more near-term opportunities for further non-dilutive development support Shares on issue 111,235,000 Issued Capital held b
Slide 17: Starpharma: Investment Highlights
Starpharma: Investment Highlights • Dominant global position in Nanopharmaceuticals • Product focus: VivaGel™ - significant global market opportunity for HIV and other STI’s • Leverage of shareholders’ investment through public funding • Industry-leading expertise in the development of dendrimers fo
Slide 18: Top Nanotech Buys for 2005
“Top “TopNanotech NanotechBuys Buysfor for2005” 2005” Forbes/Wolfe Forbes/Wolfe “Top “Top55Nanotech NanotechBreakthroughs Breakthroughs “Growth “GrowthStrategy StrategyLeadership LeadershipAward Awardininthe the for for 2004” 2004” World Nanobiotechnology Market” Forbes/Wolfe World Nanobiotechnology
Starpharma Holdings — Australian Biotechnology Expo 2005 on 6ix